| 1 |
35105904 | Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene. | 2022 Feb 1 |
1 |
| 2 |
33319669 | Resistance to Intervention: Paclitaxel in Breast Cancer. | 2021 |
1 |
| 3 |
33377156 | Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report. | 2021 Mar 3 |
1 |
| 4 |
33859743 | Tumor suppressor DRD2 facilitates M1 macrophages and restricts NF-κB signaling to trigger pyroptosis in breast cancer. | 2021 |
1 |
| 5 |
33996534 | The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report. | 2021 |
1 |
| 6 |
32194804 | Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets. | 2020 |
1 |
| 7 |
32724113 | Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. | 2020 Jul 28 |
1 |
| 8 |
32861273 | Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. | 2020 Oct |
1 |
| 9 |
33457057 | Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations. | 2019 Jul |
3 |
| 10 |
29189915 | Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. | 2018 Feb |
1 |
| 11 |
27739325 | A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. | 2017 Feb |
1 |
| 12 |
28604461 | Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents. | 2017 Oct |
1 |
| 13 |
27113739 | Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. | 2016 May |
2 |
| 14 |
25445425 | Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. | 2015 Apr |
1 |
| 15 |
25481791 | Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. | 2015 Jan |
1 |
| 16 |
25499884 | Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. | 2015 Aug 1 |
4 |
| 17 |
25583261 | BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. | 2015 Jan 13 |
8 |
| 18 |
24847251 | Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer. | 2014 Jan |
1 |
| 19 |
23265709 | Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. | 2013 Apr |
1 |
| 20 |
23326344 | BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy. | 2013 |
1 |
| 21 |
23462720 | BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. | 2013 Apr 2 |
2 |
| 22 |
23522120 | Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient. | 2013 Mar 22 |
1 |
| 23 |
23964347 | Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study. | 2013 |
1 |
| 24 |
21296416 | BRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells. | 2011 Feb |
8 |
| 25 |
21781528 | [The correlation between chemotherapeutic efficacy and breast cancer susceptibility gene 1 and class IIIβ-tubulin protein expression in non-small cell lung cancer patients]. | 2011 Jun |
1 |
| 26 |
19442054 | A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. | 2009 May |
1 |
| 27 |
19551867 | BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells. | 2009 Dec 15 |
5 |
| 28 |
19697632 | Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy. | 2009 |
3 |
| 29 |
19955925 | Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients? | 2009 Dec |
1 |
| 30 |
18547621 | Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. | 2008 Aug |
1 |
| 31 |
19002265 | Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. | 2008 |
1 |
| 32 |
19690636 | BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells. | 2007 Mar 2 |
1 |
| 33 |
16639080 | BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. | 2006 May |
7 |
| 34 |
16982732 | A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. | 2006 Sep 15 |
3 |
| 35 |
15607317 | Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. | 2005 Jan |
1 |
| 36 |
12717416 | Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. | 2003 Apr 24 |
4 |
| 37 |
14559807 | BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. | 2003 Oct 1 |
1 |
| 38 |
11295099 | Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines. | 2001 May-Jun |
1 |
| 39 |
11562742 | Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells. | 2001 Oct |
1 |
| 40 |
11593420 | BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. | 2001 Sep 27 |
2 |
| 41 |
11641785 | Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. | 2001 Oct 4 |
1 |